The C-suite shuffle: Oncopeptides, Zymeworks replace execs to start 2023
Two biotechs are shuffling their C-suites as the calendar turns to the new year: Oncopeptides and Zymeworks.
Oncopeptides announced Wednesday that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
